Equities research analysts at StockNews.com assumed coverage on shares of Ekso Bionics (NASDAQ:EKSO – Get Rating) in a research note issued to investors on Sunday. The firm set a “sell” rating on the stock.
Separately, HC Wainwright cut their price target on Ekso Bionics from $11.00 to $9.00 and set a “buy” rating on the stock in a research report on Friday, July 29th.
Ekso Bionics Stock Performance
NASDAQ EKSO opened at $2.20 on Friday. The company has a debt-to-equity ratio of 0.06, a quick ratio of 7.48 and a current ratio of 8.16. Ekso Bionics has a fifty-two week low of $1.53 and a fifty-two week high of $5.17. The company has a market cap of $28.67 million, a P/E ratio of -2.22 and a beta of 1.77. The business’s 50 day moving average price is $2.07 and its 200-day moving average price is $2.18.
Institutional Inflows and Outflows
A number of large investors have recently bought and sold shares of EKSO. Golden State Wealth Management LLC bought a new stake in shares of Ekso Bionics in the 4th quarter worth $41,000. Renaissance Technologies LLC boosted its position in Ekso Bionics by 153.4% during the second quarter. Renaissance Technologies LLC now owns 44,606 shares of the company’s stock valued at $74,000 after purchasing an additional 27,006 shares during the last quarter. Finally, Essex Investment Management Co. LLC acquired a new stake in shares of Ekso Bionics in the first quarter worth about $484,000. Institutional investors own 12.47% of the company’s stock.
Ekso Bionics Company Profile
Ekso Bionics Holdings, Inc designs, develops, sells, and rents exoskeleton products in the Americas, Europe, the Middle east, Africa, the Asia Pacific, and internationally. The company operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets.
- Get a free copy of the StockNews.com research report on Ekso Bionics (EKSO)
- Stock Market: 3 Islands Of Strength In A Sea Of Red
- 3 Banks Worth Considering For Q4
- Is There a Cure for What is Ailing Teladoc Stock?
- No One Told These 3 Stocks It’s a Down Week
- MarketBeat: Week in Review 9/12 – 9/16
Receive News & Ratings for Ekso Bionics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ekso Bionics and related companies with MarketBeat.com's FREE daily email newsletter.